Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ヴァルムエックス (VarmX)、日本の規制当局である医薬品医療機器総合機構 (PMDA) からリード資産VMX-C001に対する第I相試験免除を取得 日本の規制当局である医薬品医療機器総合機構 (PMDA)...
-
Drug developer VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001, enabling it to go straight to Phase 3 studies in Japan.
-
Foundation for Sarcoidosis Research acknowledges results of aTyr Pharma’s Phase 3 trial of efzofitimod in pulmonary sarcoidosis.
-
August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market ...
-
透过会议奖励旅游、娱乐及体育盛事带领澳门非博彩多元化 2025年第二季度经调整EBITDA为36亿元，按年上升12%，按季上升8% 宣布派发中期股息每股0.70元 澳门银河 嘉佩乐独家私人预览深受高价值顾客好评 ...
-
Galaxy Entertainment Group Q2 & Interim 2025 Results
-
Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment...
-
July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX),...
-
In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation MILAN, Italy, July 11, 2025 – Italfarmaco S.p.A. announced...
-
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a...